{"title":"非典型抗精神病药物抑制C57BL/6J小鼠骨小梁增生。","authors":"Xingsheng Li, Tim R Nagy","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To investigate the effects of the atypical antipsychotics drugs (AADs), olanzapine and risperidone, on femoral bone characteristics in female C57BL/6J mice.</p><p><strong>Methods: </strong>Mice were treated with placebo or AADs (olanzapine or risperidone) for 3-4 weeks. Femoral cortical and trabecular bone characteristics were determined using micro-computed tomography.</p><p><strong>Results: </strong>Olanzapine-treated mice tended to have lower trabecular bone volume (<i>P</i> = 0.088) and connectivity (<i>P</i> = 0.057) but no significant differences in bone density (<i>P</i> = 0.521) relative to controls. Risperidone-treated mice had significantly lower trabecular bone density (<i>P</i> = 0.001) and volume (<i>P</i> = 0.008), bone volume/total volume (<i>P</i> = 0.001), connectivity (<i>P</i> = 0.007), and trabecular number (<i>P</i> = 0.003) relative to controls. Cortical bone was not significantly affected by olanzapine or risperidone treatment.</p><p><strong>Conclusion: </strong>AADs inhibited trabecular bone accrual in C57BL/6J mice suggesting that alternative treatment options may need to be considered for the schizophrenia patient with potential osteoporosis risk.</p>","PeriodicalId":87474,"journal":{"name":"International journal of body composition research","volume":"11 1","pages":"21-24"},"PeriodicalIF":0.0000,"publicationDate":"2013-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4023556/pdf/nihms460430.pdf","citationCount":"0","resultStr":"{\"title\":\"Atypical antipsychotic drugs inhibit trabecular bone accrual in C57BL/6J mice.\",\"authors\":\"Xingsheng Li, Tim R Nagy\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>To investigate the effects of the atypical antipsychotics drugs (AADs), olanzapine and risperidone, on femoral bone characteristics in female C57BL/6J mice.</p><p><strong>Methods: </strong>Mice were treated with placebo or AADs (olanzapine or risperidone) for 3-4 weeks. Femoral cortical and trabecular bone characteristics were determined using micro-computed tomography.</p><p><strong>Results: </strong>Olanzapine-treated mice tended to have lower trabecular bone volume (<i>P</i> = 0.088) and connectivity (<i>P</i> = 0.057) but no significant differences in bone density (<i>P</i> = 0.521) relative to controls. Risperidone-treated mice had significantly lower trabecular bone density (<i>P</i> = 0.001) and volume (<i>P</i> = 0.008), bone volume/total volume (<i>P</i> = 0.001), connectivity (<i>P</i> = 0.007), and trabecular number (<i>P</i> = 0.003) relative to controls. Cortical bone was not significantly affected by olanzapine or risperidone treatment.</p><p><strong>Conclusion: </strong>AADs inhibited trabecular bone accrual in C57BL/6J mice suggesting that alternative treatment options may need to be considered for the schizophrenia patient with potential osteoporosis risk.</p>\",\"PeriodicalId\":87474,\"journal\":{\"name\":\"International journal of body composition research\",\"volume\":\"11 1\",\"pages\":\"21-24\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2013-01-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4023556/pdf/nihms460430.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International journal of body composition research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International journal of body composition research","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Atypical antipsychotic drugs inhibit trabecular bone accrual in C57BL/6J mice.
Objective: To investigate the effects of the atypical antipsychotics drugs (AADs), olanzapine and risperidone, on femoral bone characteristics in female C57BL/6J mice.
Methods: Mice were treated with placebo or AADs (olanzapine or risperidone) for 3-4 weeks. Femoral cortical and trabecular bone characteristics were determined using micro-computed tomography.
Results: Olanzapine-treated mice tended to have lower trabecular bone volume (P = 0.088) and connectivity (P = 0.057) but no significant differences in bone density (P = 0.521) relative to controls. Risperidone-treated mice had significantly lower trabecular bone density (P = 0.001) and volume (P = 0.008), bone volume/total volume (P = 0.001), connectivity (P = 0.007), and trabecular number (P = 0.003) relative to controls. Cortical bone was not significantly affected by olanzapine or risperidone treatment.
Conclusion: AADs inhibited trabecular bone accrual in C57BL/6J mice suggesting that alternative treatment options may need to be considered for the schizophrenia patient with potential osteoporosis risk.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
